Motixafortide

What is Motixafortide?

Motixafortide is a synthetic cyclic peptide that blocks the chemokine receptor CXCR4, used with filgrastim to drive haematopoietic stem cells out of the bone marrow and into the bloodstream so they can be collected by apheresis before an autologous transplant in multiple myeloma. It is sold as Aphexda and was approved by the FDA on 8 September 2023. The molecule is 14 residues closed by a disulfide bond between positions 4 and 13, with a 4-fluorobenzoyl cap, two citrullines, a naphthylalanine and a D-lysine — 2,160 daltons of heavily modified peptide. Its defining pharmacological oddity is a mismatch between how long it lasts in blood and how long it works: the effective plasma half-life is about two hours, but it dissociates from CXCR4 so slowly that receptor occupancy is maintained beyond 72 hours, which is why a single injection the evening before apheresis is enough.

What Motixafortide Is Investigated For

Motixafortide has one approval, one pivotal trial, and a sizeable discrepancy inside that trial worth understanding before quoting any number from it. GENESIS randomised 122 multiple myeloma patients 2:1 to motixafortide plus filgrastim or placebo plus filgrastim, with the primary endpoint being collection of at least 6 × 10⁶ CD34+ cells per kilogram in up to two apheresis procedures. The Nature Medicine publication reports 92.5% versus 26.2%; the FDA label reports 67.5% versus 9.5%. Both are from the same patients. The difference is which laboratory counted: the published analysis used local laboratory values, which were also what clinicians acted on during the trial, while the FDA's efficacy results used the central laboratory. Whichever is quoted, the effect is large and the single-apheresis result is the more striking comparison — 88.8% versus 9.5% locally, 63.8% versus 2.4% centrally. Outside that indication the evidence is early but genuinely interesting. A single injection in healthy volunteers collected a mean of 11.6 × 10⁶ CD34+ cells/kg in one day. In pancreatic cancer, where the CXCL12–CXCR4 axis excludes T cells from tumours, the COMBAT trials and a 2026 eleven-patient study combining motixafortide with cemiplimab and chemotherapy have reported response rates well above what chemotherapy alone achieves in that disease — in a single-arm setting, in very small numbers, with a randomised comparison ongoing.

History & Discovery

Motixafortide has one of the longer and stranger provenances in the peptide catalogue, and none of it was aimed at where the drug ended up. It begins with polyphemusin II, an antimicrobial peptide from the haemocytes of the horseshoe crab. In the 1990s at Kyoto University, Nobutaka Fujii and Hirokazu Tamamura set out to build HIV entry inhibitors and worked outward from a polyphemusin II analogue they called T22. The target was CXCR4, the coreceptor that T-cell-tropic HIV-1 strains use to enter cells. T22 was effective but extremely basic — five arginines and three lysines — and the group had already observed that in this family total positive charge tracked both anti-HIV activity and cytotoxicity. Shortening gave T134, and replacing a residue with 3-(2-naphthyl)alanine gave T140, the most potent of the series. Alanine scanning then identified four indispensable residues, and systematic citrulline substitutions reduced the net charge while preserving activity, producing analogues with far better selectivity indices and complete serum stability. TN14003 came out of that work; capping it with 4-fluorobenzoic acid gave 4F-benzoyl-TN14003. The HIV programme did not reach the clinic. The molecule found a second life in oncology, developed by Biokine Therapeutics in Israel as BKT140 and licensed to BioLineRx as BL-8040. Preclinical work through the early 2010s showed preferential cytotoxicity toward haematopoietic malignant cells and tumour growth reduction in leukaemia, myeloma, CML and lung cancer models — but the finding that mattered commercially was more mundane. The same receptor that HIV exploits is the anchor that holds haematopoietic stem cells in the bone marrow, and blocking it releases them. A 2014 phase 1 in multiple myeloma and a 2017 healthy-volunteer study established that a single injection could mobilise enough cells for collection in a day. GENESIS ran from 2017 and read out in 2023, and the FDA approved Aphexda on 8 September 2023. The commercial story afterwards was less triumphant than the pharmacology. In November 2024 BioLineRx licensed the drug exclusively to Ayrmid Ltd for all indications except solid tumours and all territories except Asia, to be commercialised through Ayrmid's subsidiary Gamida Cell, shut down its own US commercial operation, and refocused on development in Israel — keeping the pancreatic cancer programme, which is the part of the original oncology thesis still being pursued.

How It Works

Stem cells sit inside bone marrow held in place by a molecular tether: a receptor on the stem cell called CXCR4 grips a signal, CXCL12, produced by the marrow around it. Growth factor injections alone loosen that grip enough to push some cells into the blood. Motixafortide blocks the receptor outright, so the tether releases and far more cells wash into circulation, where a machine can filter them out.

Motixafortide inhibits C-X-C motif chemokine receptor 4 (CXCR4) and blocks binding of its ligand, stromal-derived factor-1α, also called CXCL12. That axis governs the trafficking and homing of haematopoietic stem and progenitor cells to the marrow compartment, where CXCR4 anchors them to the marrow matrix either directly through CXCL12 or by inducing other adhesion molecules. Blocking it releases cells into circulation, producing leukocytosis and a rise in circulating stem and progenitor cells in mice, rats, dogs and humans; cells mobilised this way engraft with long-term repopulating capacity in rodent transplant models. The binding kinetics are what distinguish the molecule. In vitro the half-maximal inhibitory concentration against CXCR4 is 0.42 to 4.5 nM, binding affinity is 7.9 picomolar, and the dissociation rate constant is 3.38 × 10⁻⁵ per second — slow enough that receptor occupancy is maintained for more than 72 hours. Set against an effective plasma half-life of roughly two hours, this is a drug whose duration of action is governed by how long it takes to leave the receptor rather than by how long it stays in the blood. Molecular dynamics work has characterised the interaction: six cationic residues form charge interactions with acidic receptor residues, while two bulky synthetic moieties work in tandem to restrict the conformational changes associated with receptor activation, stabilising inactive states. Earlier pharmacology characterised the parent compound as an inverse agonist rather than a neutral antagonist at CXCR4. The pharmacodynamic consequence is a large, rapid shift in circulating cells. In healthy volunteers given motixafortide alone, CD34+ counts rose to a maximum at 16 hours and were still well above baseline at 24. In GENESIS, the median fold increase in peripheral blood CD34+ count over the 24 hours spanning a single dose was 6.7 with motixafortide against 1.5 with placebo. The cells collected are not merely more numerous: immunophenotyping and single-cell RNA expression profiling showed preferential mobilisation of more primitive haematopoietic stem and progenitor cells. Pharmacokinetics are straightforward. After subcutaneous injection the peak comes at roughly 15 minutes to 70 minutes, protein binding exceeds 99%, the central volume of distribution is 27 L, and apparent clearance is 46.5 L/hour. Catabolism is non-specific degradation into small peptides and amino acids in blood and liver microsomes, with no unique human metabolites identified. Renal and mild hepatic impairment do not meaningfully affect exposure, and because the drug is given as one or two doses rather than chronically, the risk from increased exposure in more severe impairment is considered low.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Motixafortide:

• 01How it compares with plerixafor. No head-to-head trial exists, the only comparative review says so explicitly, and the ASCO guideline lists both without preference — so the choice between them currently rests on tolerability, administration logistics and institutional practice rather than on evidence of differential efficacy.
• 02Why the local and central laboratory analyses of GENESIS differ by roughly 25 percentage points on the same endpoint in the same patients, and whether that gap reflects anything clinically meaningful about assay variability near the collection threshold.
• 03Whether a single dose is the right dose. Receptor occupancy is maintained beyond 72 hours, which raises the question of whether the permitted second dose before a third apheresis adds anything, and whether lower doses would mobilise adequately with fewer injection-site reactions.
• 04Its role in gene and cell therapy, where the required CD34+ numbers far exceed what transplantation needs and where G-CSF cannot safely be used in sickle cell disease. This is the clearest place the drug could fill a genuine gap, and the human data amount to a healthy-volunteer study and an allogeneic donor study.
• 05Whether the pancreatic cancer signal survives randomisation. An eleven-patient single-arm study reporting 64% objective response in metastatic pancreatic adenocarcinoma is remarkable enough to demand a controlled trial, which is under way; the earlier COMBAT trials were also single-arm.
• 06Whether mobilising more primitive progenitors translates into better clinical outcomes. The single-cell profiling showed the cell product differs qualitatively, not just quantitatively, but engraftment times and graft durability were similar between arms, so no outcome benefit has been demonstrated from that difference.
• 07Whether the premedication regimen is optimal. It was introduced partway through GENESIS as hypersensitivity emerged, and only 14 of 92 treated patients received the full triple combination — so the regimen now required by the label was never prospectively evaluated against alternatives.

Forms & Administration

Subcutaneous injection, prepared and given by healthcare professionals in a setting equipped to manage anaphylaxis. It comes as a lyophilised powder in single-dose vials containing 73 mg, reconstituted with 2 mL of 0.45% sodium chloride (or 1 mL sterile water plus 1 mL of 0.9% sodium chloride) to give 36.5 mg/mL, from which up to 1.7 mL — 62 mg — is withdrawn. More than one vial is usually needed, since dosing is 1.25 mg/kg by actual body weight. The injection goes slowly, over about two minutes, into the abdomen, the back or sides of the upper arms, or the thighs; no single injection may exceed 2 mL, so larger doses are split across several syringes and sites at least 2 cm apart, avoiding a 5 cm circle around the navel. Reconstituted solution may be held for up to 24 hours refrigerated or at room temperature, protected from light. Premedication with an H1-antihistamine, an H2 blocker, a leukotriene inhibitor and an analgesic goes in 30 to 60 minutes beforehand, and patients are observed for an hour afterwards.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Motixafortide is a prescription oncology product administered by healthcare professionals in a setting equipped to treat anaphylaxis, as part of a stem cell transplant programme. It is approved only in combination with filgrastim for mobilisation in multiple myeloma, and is explicitly not for use in patients with leukaemia. The figures above describe approved practice and are not guidance for anyone to act on independently.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Motixafortide Is NOT For

Drug & Supplement Interactions

No clinically significant pharmacokinetic drug interactions have been established, and the molecule's disposition makes them unlikely: motixafortide is catabolised non-specifically into small peptides and amino acids in blood and liver microsomes rather than by cytochrome P450 enzymes, and it is given as a single dose or two. The interactions that matter are pharmacodynamic and procedural. Filgrastim is not an interaction but a required partner — the drug is approved only in combination with it, and the mobilisation effect of the pair substantially exceeds either alone. The triple premedication regimen is likewise part of the prescribed therapy rather than an adjunct: an H1-antihistamine, an H2 blocker and a leukotriene inhibitor 30 to 60 minutes before every dose, with an analgesic recommended in addition. One genuine interaction is spelled out on the label. Patients taking negative chronotropic drugs, particularly beta-blockers, may be at greater risk of hypotension if a hypersensitivity reaction occurs, because the usual compensatory response is blunted and adrenaline is harder to work with; the label suggests replacing beta-blockers with non-chronotropic alternatives where appropriate. Separately, the thorough QT study found concentration-dependent QTcI prolongation with a mean placebo-corrected increase of 11 msec at 1.7 times the maximum recommended exposure, which is modest but worth holding in mind alongside other QT-prolonging drugs in a patient who may also be receiving antiemetics and antibiotics around the time of transplant.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions